glp 1 accessibility Global Perspectives on Discover How GLP-1 Trials Are

2017;29(S1):S314

TRIUMPH is retatrutide's Phase 3 program: eight trials across obesity, type 2 diabetes, knee osteoarthritis, sleep apnea, cardiovascular disease, and liver disease populations

Focusing on scale weight as your marker of progress can miss the mark on improved body composition

"Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study"

Peripheral nerve function was assessed by nerve conduction velocities, amplitudes and Fwaves on the motor and sensory nerves

[1] These effects are typically dose-dependent, most pronounced during dose escalation, and tend to diminish over time